Results 281 to 290 of about 3,569,968 (400)

Chimeric Nanozyme Bacterial Outer Membrane Vesicles Reprograming Tumor Microenvironment for Safe and Efficient Anticancer Therapy

open access: yesAdvanced Science, EarlyView.
This study reports an innovative strategy to improve the safety of OMVs by shielding them with a sophisticated shell composed of DaFe shell and Au nanoparticles, which not only reduces the toxicity of OMVs during circulation but also enables rapid release of these therapeutically active components in tumor for combined therapy involving glucose ...
Fan Zhang   +11 more
wiley   +1 more source

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. [PDF]

open access: yesBlood Cancer J
Chunara F   +15 more
europepmc   +1 more source

Bioengineered Tumor‐Derived Extracellular Vehicles Suppressed Colorectal Cancer Liver Metastasis and Bevacizumab Resistance

open access: yesAdvanced Science, EarlyView.
The upregulated CCL24 in CRC liver metastasis promotes the formation of inflammatory tumor‐associated fibroblast subsets and induces resistance to bevacizumab therapy. Downregulation of CCL24 significantly increased sensitivity to antiangiogenic therapy in CRC mouse model. Hence, a novel therapeutic target is identified for patients with CRC with liver
Junjiang Wang   +7 more
wiley   +1 more source

Nucleotides as an Anti‐Aging Supplementation in Older Adults: A Randomized Controlled Trial (TALENTs study)

open access: yesAdvanced Science, EarlyView.
The TALENTs randomized controlled trial evaluates the potential of nucleotides supplementation as an anti‐aging intervention in older adults. After 19 weeks, nucleotides supplementation significantly reduces DNA methylation age, suggesting a delay in epigenetic aging, and improves insulin sensitivity without severe adverse events.
Shuyue Wang   +9 more
wiley   +1 more source

A Self‐Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple‐Negative Breast Cancer Therapy

open access: yesAdvanced Science, EarlyView.
A CTGF‐LYTAC nanoplatform is developed to selectively degrade connective tissue growth factor (CTGF) in triple‐negative breast cancer (TNBC), inhibiting TGF‐β signaling and cell interactions in the tumor microenvironment (TME). This strategy effectively suppresses tumor growth and metastasis, outperforming antibody‐based therapy.
Jia‐Yi Lin   +11 more
wiley   +1 more source

Improving hydration among hospitalised older adults in an acute geriatric ward with a bundled multi-component intervention. [PDF]

open access: yesBMJ Open Qual
Tan SLL   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy